检索结果-南通市图书馆

Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil

World Journal of Gastroenterology 2019年第38期25卷 5862-5882页

作者： rogerio serafim Parra Julio MF Chebli Heda MBs Amarante Cristina Flores Jose ML Parente Odery Ramos Milene Fernandes Jose JR Rocha Marley R Feitosa Omar Feres Antonio s scotton Rodrigo B Nones Murilo M Lima Cyrla Zaltman Carolina D Goncalves Isabella M Guimaraes Genoile O santana Ligia Y sassaki rogerio s hossne Mauro Bafutto Roberto LK Junior Mikaell AG Faria sender J Miszputen Tarcia NF Gomes Wilson R Catapani Anderson A Faria stella Cs souza Rosana F Caratin Juliana T senra Maria LA Ferrari Department of surgery and Anatomy Ribeirao Preto Medical SchoolUniversity of Sao PauloRibeirao PretoSP 14049-900Brazil Hospital Universitario da Universidade Federal do Piaui TeresinaPI 64049-550Brazil Carolina D Gonclves Isabella M GuimaraesUniversidade Federal do Rio de JaneiroRio de JaneiroRJ 21941-913Brazil Universidade do Estado da Bahia -SalvadorBA 41150-000Brazil Department of Internal Medicine Botucatu Medical School at Sao Paulo State University(UNESP)BotucatuSP 18618-687Brazil Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda GoianiaGO 74535-170Brazil Kaiser Clinica Sao Jose do Rio PretoSP 15015-110Brazil Escola Paulista de Medicina Sao PauloSP 04023-900Brazil UNIFEsP Disciplina de GastroenterologiaSao PauloSP 04040-002Brazil Faculdade de Medicina do ABC Santo AndreSP 09060-870Brazil Faculdade de Medicina UFMG Belo HorizonteMG30130-100Brazil Inflammatory Bowel Disease Center Federal University of Juiz de ForaJuiz de ForaMG 36036-247Brazil Takeda Pharmaceuticals Brazil Sao PauloSP 04709-011Brazil 不详 Hospital de Clinicas da Universidade Federal do Parana CuritibaPR 80060-900Brazil Hospital de Clinicas de Porto Alegre Porto Alegre-RS 90035-007Brazil Universidade Federal do Piaui TeresinaPI 64073-500Brazil Hospital de Clínicas da Universidade Federal do Parana CuritibaPR 80060-900Brazil CTI Clinical Trial&Consulting services Lisbon 1070-274Portugal CMIP Centro Mineiro de Pesquisa Juiz de ForaMG 36010-570Brazil Hospital Nossa senhora das Gracas CuritibaPR 80810-040Brazil

BACKGROUND Inflammatory bowel diseases(IBD)have been associated with a low quality of life(QoL)and a negative impact on work productivity compared to the general *** about disease control,patient-reported outcomes(PROs),treatment patterns and use of healthcare resources is relevant to optimizing IBD *** To describe QoL and work productivity and activity impairment(WPAI),treatment patterns and use of healthcare resources among IBD patients in *** A multicenter cross-sectional study included adult outpatients who were previously diagnosed with moderate to severe Crohn’s disease(CD)or ulcerative colitis(UC).At enrolment,active CD and UC were defined as having a Harvey Bradshaw Index≥8 or a CD Activity Index≥220 or calprotectin>200μg/g or previous colonoscopy results suggestive of inadequate control(per investigator criteria)and a 9-point partial Mayo score≥5,*** PRO assessment included the QoL questionnaires sF-36 and EQ-5D-5L,the Inflammatory Bowel Disease Questionnaire(IBDQ),and the WPAI *** about healthcare resources and treatment during the previous 3 years was collected from medical ***-square,Fisher’s exact and student’s t-/Mann-Whitney U tests were used to compare PROs,treatment patterns and the use of healthcare resources by disease activity(α=0.05).REsULTs Of the 407 patients in this study(CD/UC:64.9%/35.1%,mean age 42.9/45.9 years,54.2%/56.6%female,38.3%/37.1%employed),44.7%/25.2%presented moderate-to-severe CD/UC activity,respectively,at *** in median values for CD/UC,respectively,the sF-36 physical component was 46.6/44.7 and the mental component was 45.2/44.2,the EQ-visual analog scale score was 80.0/70.0,and the IBDQ overall score was 164.0/*** to severe activity,female gender,being unemployed,a lower educational level and lower income were associated with lower QoL(Ps 20%and 5%for CD and UC patients,re

关键词： Inflammatory bowel disease Crohn’s disease Ulcerative colitis Quality of life Healthcare resources

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Modern surgical strategies for perianal Crohn's disease

引用

World Journal of Gastroenterology 2020年第42期26卷 6572-6581页

作者： Gilmara Pandolfo Zabot Ornella Cassol rogerio saad-hossne Willem Bemelman Department of Coloproctology Hospital Moinhos de VentoPorto Alegre 90035-902RSBrazil Department of surgery Hospital de Clínicas de Passo FundoPasso Fundo 99010-260RSBrazil Department of Internal Medicine São Paulo State University(Unesp)Medical SchoolBotucatu 18618687São PauloBrazil Department of surgery Amsterdam University Medical CenterUniversity of AmsterdamAmsterdam 19268Netherlands

One of the most challenging phenotypes of Crohn’s disease is perianal fistulizing disease(PFCD).It occurs in up to 50%of the patients who also have symptoms in other parts of the gastrointestinal tract,and in 5%of the cases it occurs as the first *** is associated with severe symptoms,such as pain,fecal incontinence,and a significant reduction in quality of *** presence of perianal disease in conjunction with Crohn’s disease portends a significantly worse disease *** patients require close monitoring to identify those at risk of worsening disease,suboptimal biological drug levels,and signs of developing *** last 2 decades have seen significant advancements in the management of *** recently,newer biologics,cell-based therapies,and novel surgical techniques have been introduced in the hope of improved ***,in refractory cases,many patients face the decision of having a stoma made and/or a proctectomy *** this review,we describe modern surgical management and the most recent advances in the management of complex PFCD,which will likely impact clinical practice.

关键词： Crohn’s disease Inflammatory bowel disease surgical treatment Perianal fistulas Anorectal fistula

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Epidemiology of inflammatory bowel diseases in the state of Rio Grande do sul,Brazil

引用

World Journal of Gastroenterology 2022年第30期28卷 4174-4181页

作者： Ornella sari Cassol Gilmara Pandolfo Zabot rogerio saad-hossne Alexandre Padoin Department of Coloproctology IMED Medical SchoolPasso Fundo 99010260RSBrazil Graduate Program in Medicine and Health sciences Pontifícia Universidade Católica do Rio Grande do Sul(PUCRS)Porto Alegre 90610001RSBrazil Department of Coloproctology Coloprocto Canoas ClinicCanoas 92310205RSBrazil Department of Coloproctology Hospital Moinhos de Vento(HMV)Porto Alegre 90035000RSBrazil Department of surgery and Orthopaedics Universidade Estadual Paulista(UNESP)Botucatu 18618687SPBrazil

BACKGROUND This is the first study on the epidemiology of inflammatory bowel diseases(IBDs)in Rio Grande do sul(Rs),the southernmost state of Brazil with the country’s fifth largest ***’s disease(CD)and ulcerative colitis(UC)are collectively termed *** have high incidence and prevalence rates in highincome countries,although in recent years there has been a change in the classic geographical distribution of IBDs,with growing rates in traditionally lowincidence *** To estimate the incidence and prevalence of IBDs in the Rs state,Brazil,between 2014 and *** This is a cross-sectional descriptive observational *** with IBD who had initiated treatment and met the inclusion criteria of the Rs state free drug distribution program were *** were obtained from registration or renewal records of the Rs state specialty *** male,female,and total populations were estimated according to mid-year data from the Brazilian Institute of Geography and statistics,which served as a reference for calculating the incidence and prevalence rates of IBDs during the study *** were described using mean,standard deviation,and *** We included 1082 patients with IBD,of whom 57.5%were female and 42.5% were *** with CD accounted for 72.45% of the sample,and those with UC accounted for 27.54%.IBD prevalence during the study period was 9.51 per 100000 population,of which 6.89 corresponded to people with CD and 2.62,to people with *** rates per 100000 population/year were 2.54 in 2014,2.61 in 2015,1.91 in 2016,0.80 in 2017,0.83 in 2018,and 0.96 in *** mean IBD incidence rate per 100000 population was 1.61,of which 1.17 corresponded to CD and 0.44,to *** mean age was 41 years,and patients were mostly aged 30-40 *** by region was higher in the state capital metropolitan area:12.69 per 100000 *** Our results demonstrated an IBD prevalence of 9.51% and incidence of

关键词： Inflammatory bowel diseases Crohn’s disease Ulcerative colitis Epidemiology Incidence Prevalence

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Quality of care in patients with inflammatory bowel disease from a public health center in Brazil

引用

World Journal of Clinical Cases 2022年第33期10卷 12184-12199页

作者： Debora Mayumi Takamune Giovana signorelli Astolfi Cury Giulia Ferrás Giedre soares Prates Herrerias Adriana Rivera Jaqueline Ribeiro Barros Julio Pinheiro Baima rogerio saad-hossne Ligia Yukie sassaki Department of Internal Medicine São Paulo State University(Unesp)Medical SchoolBotucatu 18618686São PauloBrazil Research Unit Virgen Macarena University HospitalSeville 41009Spain Department of Medicine Nove de Julho UniversityBauru 17011-102São PauloBrazil Department of surgery São Paulo State University(Unesp)Medical SchoolBotucatu 18618686São PauloBrazil

BACKGROUND Inflammatory bowel diseases(IBDs)are chronic diseases that demand continuous interaction between patients and healthcare *** of care(QoC)is a factor that contributes to a patient’s adherence to treatment and its *** To evaluate QoC in patients from a single IBD reference *** This cross-sectional study included 133 patients from a single Brazilian IBD public health *** was evaluated through the QoC Through the Eyes of Patients with IBD(QUOTE-IBD)questionnaire(based on patient perspectives),which measures eight dimensions of *** compared QoC among patients with Crohn’s disease and ulcerative colitis and analyzed the clinical and psychological factors associated with QoC *** evaluations assessed disease characteristics,quality of life,anxiety,and depression *** sixty-nine patients with Crohn’s disease and 64 with ulcerative colitis were *** mean age was 37.26 years±13.05 years,and 63.91%of the patients were *** mean duration of the disease was 8.44 years±7.59 years,where most patients were in remission(70.31%of patients with ulcerative colitis and 62.32%with Crohn’s disease).The total QoC score of the sample was 8.61 years±1.31 points,indicating that the QoC provided by the center was *** to univariate logistic regression,patients with Crohn’s disease had higher satisfaction rates than those with ulcerative colitis[odds ratio(OR):2.746;95%confidence interval(CI):1.360-5.541;P=0.0048]and patients on infliximab(OR:2.175;95%CI:1.037-4.562;P=0.0398).CONCLUsION Patients from the IBD public center reported good doctor-patient relationships,but had problems related to the healthcare *** of healthcare centers is of paramount to improve QoC for the patients involved.

关键词： QUOTE-IBD questionnaire Quality of care Crohn’s disease Ulcerative colitis Inflammatory bowel disease Doctor-patient relationship

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Intestinal complications in Brazilian patients with ulcerative colitis treated with conventional therapy between 2011 and 2020

引用

World Journal of Gastroenterology 2023年第8期29卷 1330-1343页

作者： Adalberta Lima Martins Rodrigo Galhardi Gasparini Ligia Yukie sassaki rogerio saad-hossne Alessandra Mileni Versut Ritter Tania Biatti Barreto Taciana Marcolino Claudia Yang santos Espirito santo Health Office State Office for Pharmaceutical AssistanceEspirito Santos 29056-030Brazil Department of Gastroenterology Specialized Medical CenterMarília 17502-020Brazil Department of Gastroenterology Sao Paulo State UniversityMedical SchoolBotucatu 18618-687Brazil Real World Evidence IQVIA BrazilSao Paulo 04719-002Brazil Department of Gastroenterology Takeda Pharmaceuticals BrazilSao Paulo 04794-000Brazil

BACKGROUND This was an observational, descriptive, and retrospective study from 2011 to 2020 from the Department of Informatics of the Brazilian Healthcare system *** To describe the intestinal complications(IC) of patients with ulcerative colitis(UC) who started conventional therapies in Brazil’s public Healthcare *** Patients ≥ 18 years of age who had at least one claim related to UC 10th revision of the International statistical Classification of Diseases and Related Health Problems(ICD-10) code and at least 2 claims for conventional therapies were included. IC was defined as at least one claim of: UC-related hospitalization, procedures code for rectum or intestinal surgeries, and/or associated disease defined by ICD-10 codes(malignant neoplasia of colon, stenosis, hemorrhage, ulcer and other rectum or anus disease, megacolon, functional diarrhea volvulus, intussusception and erythema nodosum). Descriptive statistics, annual incidence, and incidence rate(IR) [per 100 patient-years(PY)] over the available follow-up period were *** In total, 41229 UC patients were included(median age, 48 years;65% women) and the median(interquartile range) follow-up period was 3.3(1.8-5.3) years. Conventional therapy used during follow-up period included: mesalazine(87%), sulfasalazine(15%), azathioprine(16%) or methotrexate(1%) with a median duration of 1.9(0.8-4.0) years. Overall IR of IC was 3.2 cases per 100 PY. Among the IC claims, 54% were related to associated diseases, 20% to procedures and 26% to hospitalizations. The overall annual incidence of IC was 2.9%, 2.6% and 2.5% in the first, second and third year after the first claim for therapy(index date), respectively. Over the first 3 years, the annual IR of UC-related hospitalizations ranged from 0.8% to 1.1%;associated diseases from 0.9% to 1.2%-in which anus or rectum disease, and malignant neoplasia of colon were the most frequently reported;and procedure events from 0.6% to 0.7%, bein

关键词： Ulcerative colitis Brazil Conventional therapy Intestinal complications Real world Public healthcare

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Treatment of acute severe ulcerative colitis using accelerated infliximab regimen based on infliximab trough level:A case report

引用

World Journal of Clinical Cases 2021年第13期9卷 3219-3226页

作者： Ana Lorena sousa de Vasconcelos Garate Thiara Barcelos Rocha Luciana Rocha Almeida Rodrigo Quera Jaqueline Ribeiro Barros Julio Pinheiro Baima rogerio saad-hossne Ligia Yukie sassaki Department of Internal Medicine São Paulo State University(Unesp)Medical SchoolBotucatu 18618687São PauloBrazil Inflammatory Bowel Disease Program GastroenterologyMedicine DepartmentClínica Universidad de los AndesSantiago 7550000Chile

BACKGROUND Acute severe ulcerative colitis (AsUC) is a complication of ulcerative colitisassociated with high levels of circulating tumor necrosis factor alpha, due to theintense inflammation and faster stool clearance of anti-tumor necrosis factordrugs. Dose-intensified infliximab treatment can be beneficial and is associatedwith lower rates of colectomy. The aim of the study was to present a case of apatient with AsUC and megacolon, treated with hydrocortisone and acceleratedscheme of infliximab that was monitored by drug trough *** sUMMARYA 22-year-old female patient diagnosed with ulcerative colitis, presented withdiarrhea, rectal bleeding, abdominal pain, vomiting, and distended *** investigation, a positive toxin for Clostridium difficile and colonic dilatationof 7 cm consistent with megacolon were observed. she was treated with oralvancomycin for pseudomembranous colitis and intravenous hydrocortisone forsevere colitis, which led to the resolution of megacolon. Due to the persistentsevere colitis symptoms, infliximab 5 mg/kg was prescribed, monitored by drugtrough level (8.8 μg/mL) and fecal calprotectin of 921 μg/g (sed onthe low infliximab trough level after one week from the first infliximab dose, thepatient received a second infusion at week 1, consistent with the acceleratedregimen (infusions at weeks 0, 1, 2 and 6). We achieved a positive clinical andendoscopic response after 6 mo of therapy, without the need for a *** accelerated infusions can be beneficial in AsUC unresponsive to thetreatment with intravenous corticosteroids. Longitudinal studies are necessary todefine the best therapeutic drug monitoring and treatment regimen for thesepatients.

关键词： Infliximab Acute severe ulcerative colitis Toxic megacolon Ulcerative colitis Inflammatory bowel disease Case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Intestinal complications in patients with Crohn's disease in the Brazilian public healthcare system between 2011 and 2020

引用

World Journal of Clinical Cases 2023年第14期11卷 3224-3237页

作者： Ligia Yukie sassaki Adalberta Lima Martins Rodrigo Galhardi-Gasparini rogerio saad-hossne Alessandra Mileni Versut Ritter Tania Biatti Barreto Taciana Marcolino Bruno Balula Claudia Yang-santos Department of Internal Medicine São Paulo State University-UNESPMedical School18618687BotucatuBrazil Department of Gastroenterology State Office for Pharmaceutical Assistance at Espírito Santo Health OfficeVitoria 29017-010Espirito SantoBrazil Department of Gastroenterology SETE–Specialized Medical CenterMarilia 17502-020Sao PauloBrazil Department of surgery São Paulo State University-UNESPMedical School18618687BotucatuBrazil Real World Evidence IQVIA Brazil04719-002Sao PauloBrazil Medical Affairs Takeda Pharmaceuticals Brazil04794-000Sao PauloBrazil Clinical Research Takeda Pharmaceuticals Brazil04794-000Sao PauloBrazil

BACKGROUND This is a secondary database study using the Brazilian public healthcare system *** To describe intestinal complications(ICs)of patients in the Brazilian public healthcare system with Crohn’s disease(CD)who initiated and either only received conventional therapy(CVT)or also initiated anti-tumor necrosis factor(anti-TNF)therapy between 2011 and *** This study included patients with CD[international classification of diseases–10th revision(ICD-10):K50.0,K50.1,or K50.8](age:≥18 years)with at least one claim of CVT(sulfasalazine,azathioprine,mesalazine,or methotrexate).IC was defined as a CD-related hospitalization,pre-defined procedure codes(from rectum or intestinal surgery groups),and/or associated disease(pre-defined ICD-10 codes),and overall(one or more type of ICs).REsULTs In the 16809 patients with CD that met the inclusion criteria,the mean follow-up duration was 4.44(2.37)*** total,14697 claims of ICs were found from 4633 *** the 1-and 5-year of follow-up,8.3%and 8.2%of the patients with CD,respectively,presented at least one IC,of which fistula(31%)and fistulotomy(48%)were the most commonly *** overall incidence rate(95%CI)of ICs was 6.8(6.5–7.04)per 100 patient years for patients using only-CVT,and 9.2(8.8–9.6)for patients with evidence of anti-TNF *** The outcomes highlighted an important and constant rate of ICs over time in all the CD populations assessed,especially in patients exposed to anti-TNF *** outcome revealed insights into the real-world treatment and complications relevant to patients with CD and highlights that this disease remains a concern that may require additional treatment strategies in the Brazilian public healthcare system.

关键词： Crohn’s disease Intestinal complications Anti-tumor necrosis factor Conventional therapy Public healthcare system

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Non-Hodgkin＇s Lymphoma： An Important Differential Diagnosis in Inflammatory Bowel Disease

引用

Chinese Medical Journal 2018年第11期131卷 1377-1378页

作者： rogerio saad-hossne Carina De Fatima De sibia Julio Pinheiro Baima Ligia Yukie sassaki Department of surgery Division of Coloproctology Botucatu Medical School Sao Paulo State University-UNESP Botucatu SP 18618-687 Brazil Department of Internal Medicine (Gastroenterology) Botucatu Medical School Sao Paulo State University-UNESP Botucatu SP 18618-687 Brazil

To the Editor： The gastrointestinal tract （GIT） is the most common extranodal location ofnon-Hodgkin＇s lymphoma, but it represents only 0.4% of primary colonic malignancies. symptoms are nonspecific and may include diarrhea, constipation, abdominal pain, weight loss, and gastrointestinal bleeding. In colon, the most common types are conventional large cell lymphoma, mucosa-associated lymphoid tissue lymphoma, and T-cell lymphoma.

关键词：

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Heart failure as an adverse effect of infliximab for Crohn's disease: A case report and review of the literature

引用

World Journal of Clinical Cases 2021年第33期9卷 10382-10391页

作者： Thais Gagno Grillo Luciana Rocha Almeida Rodrigo Fedatto Beraldo Mariana Barros Marcondes Diego Aparecido Rios Queiróz Daniel Luiz da silva Rodrigo Quera Julio Pinheiro Baima rogerio saad-hossne Ligia Yukie sassaki Department of Internal Medicine São Paulo State University(Unesp)Medical SchoolBotucatu 18618687São PauloBrazil Department of Pathology São Paulo State University(Unesp)Medical SchoolBotucatu 18618687São PauloBrazil Inflammatory Bowel Disease Program Digestive Disease Center Clínica Universidad de los AndesSantiago 7550000Chile

BACKGROUND Anti-tumor necrosis factor agents were the first biologic therapy approved for the management of Crohn's disease(CD).Heart failure(HF)is a rare but potential adverse effect of these *** objective of this report is to describe a patient with CD who developed HF after the use of *** sUMMARY A 50-year-old woman with a history of hypertension and diabetes presented with abdominal pain,diarrhea,and weight *** and enterotomography showed ulcerations,areas of stenosis and dilation in the terminal ileum,and thickening of the intestinal *** patient underwent ileocolectomy and the surgical specimen confirmed the diagnosis of stenosing *** patient started infliximab and azathioprine treatment to prevent post-surgical *** 6 mo after initiating infliximab therapy,the patient complained of dyspnea,orthopnea,and paroxysmal nocturnal dyspnea that gradually *** revealed biventricular dysfunction,moderate cardiac insufficiency,an ejection fraction of 36%,and moderate pericardial effusion,consistent with *** cardiac disease was considered an infliximab adverse effect and the drug was *** patient received treatment with diuretics for HF and showed improvement of symptoms and cardiac ***,the patient is using anti-interleukin for CD and is *** This reported case supports the need to investigate risk factors for HF in inflammatory bowel disease patients and to consider the risk-benefit of introducing infliximab therapy in such patients presenting with HF risk factors.

关键词： Heart failure Infliximab Anti-tumor necrosis factor therapy Crohn's disease Inflammatory bowel disease Case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

In vivo assessment of intratumoral aspirin injection to treat hepatic tumors

引用

World Journal of Hepatology 2013年第7期5卷 372-378页

作者： Rogério saad-hossne Fábio Vieira Teixeira Rafael Denadai Division of Coloproctology Department of Surgery Botucatu Medical School University of the State of So Paulo

AIM: To study the antineoplastic efficacy of 10% aspirin intralesional injection on VX2 hepatic tumors in a rabbit model. METHODs: Thirty-two male rabbits (age: 6-9 wk; body weight: 1700-2500 g) were inoculated with VX2 hepatic tumor cells (104 cells/rabbit) via supraumbilical median laparotomy. On day 4 post-implantation, when the tumors were about 1 cm in diameter, the rabbits were randomly divided into the following groups (n = 8 each group) to assess early (24 h) and late (7 d) antineoplastic effects of intratumoral injection of 10% bicarbonate aspirin solution (experimental groups) in comparison to intratumoral injection of physiological saline solution (control groups): group 1, 24 h control; group 2, 24 h experimental; group 3, 7 d control; group 4, 7 d experimental. The serum biochemistry profile (measurements of glycemia, alkaline phosphatase, gamma-glutamyl transferase, aspartateaminotransferase, and alanine aminotransferase) and body weight measurements were obtained for all animals at the following time points: D0, before tumor implant; D4, day of treatment; D5, day of sacrifice for groups 1 and 2; D11, day of sacrifice for groups 3 and 4. Gross assessments of the abdominal and thoracic cavities were carried out upon sacrifice. The resected liver tissues, including hepatic tumors, were qualitatively (general morphology, signs of necrosis) and quantitatively (tumor area) assessed by histopathological analysis. REsULTs: Gross examination showed no alterations, besides the left hepatic lobe tumors, had occurred in the thoracic and abdominal cavities of any animal at any time point evaluated. However, the features of the tumor foci were distinctive between the groups. Compared to the control groups, which showed normal unabated tumor progression, the aspirin-treated groups showed imprecise but limited tumor boundaries and a general red-white coloration (indicating hemorrhaging) at 24 h post-treatment, and development of yellow-white areas of a cicatricial as

关键词： Intralesional injection Intratumoral injection Aspirin Hepatic tumor VX2 Rabbit Antineoplastic Therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：